CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy

Glioblastoma (GBM) is one of the most aggressive and lethal solid tumors in human. While efficacious therapeutics, such as emerging chimeric antigen receptor (CAR)-T cells and chemotherapeutics, have been developed to treat various cancers, their effectiveness in GBM treatment has been hindered largely by the blood-brain barrier and blood-brain-tumor barriers. Human neutrophils effectively cross physiological barriers and display effector immunity against pathogens but the short lifespan and resistance to genome editing of primary neutrophils have limited their broad application in immunotherapy. Here we genetically engineer human pluripotent stem cells with CRISPR/Cas9-mediated gene knock-in to express…

• WC
  Walther Cancer Foundation
• PU
  Purdue University
• PU
  Purdue University Center for Cancer Research

  Award: P30CA023168
• NI
  National Institutes of Health

  Awards: P30CA023168, R37CA265926, R35GM119787
• DS
  Davidson School of Chemical Engineering, Purdue University
• PI
  Purdue Institute for Integrative Neuroscience, Purdue University
• NC
  National Cancer Institute

  Awards: P30CA023168, R37CA265926
• NI
  National Institute of General Medical Sciences
• DO
  Division of Cancer Epidemiology and Genetics, National Cancer Institute

  Award: R37CA265926